RU / ENG

Dear representatives of Pharma Mar,

We, members of the oncology patient community, kindly request your assistance in registering the medication Lurbinectedin (Zepzelca) in the territory of the Russian Federation.

Small cell lung cancer constitutes 10-20% of all lung cancer cases, with a high degree of malignancy and poor survival prognosis. Without effective treatment, the average survival for this diagnosis is only 2-4 months. Existing methods of therapy for the advanced form of this cancer typically provide a median survival of 6-12 months.

The issue lies in the rapid development of tumor resistance to first-line treatment, and all subsequent available therapy options in Russia show extremely weak effectiveness. Among the patients, there are many young individuals full of energy and a desire to continue treatment, but in our country, we have nothing more to offer them. Many people find themselves in a frustrating and dire situation—feeling well, on their feet, yet left waiting for deterioration and the cessation of therapy.

The medication Lurbinectedin (Zepzelca) represents an effective second-line treatment for small cell lung cancer. It has been approved by the FDA, included in NCCN recommendations, and is also part of clinical guidelines for treating this diagnosis in various countries such as Canada, the United Kingdom, Brazil, and others. Nevertheless, in Russia, this medication remains inaccessible, despite being mentioned multiple times in articles, interviews, and discussions by Russian oncologists.

Zepzelca stands as a significant hope for patients who have progressed on first-line therapy and serves as a last chance for those who have exhausted all subsequent options.

We believe that all individuals with oncological conditions, regardless of their place of residence and other factors, have the right to life and access to the opportunities offered by modern medicine, as stated in Article 25 of the Universal Declaration of Human Rights.

We hope that registering the medication Zepzelca in Russia will broaden the range of treatment possibilities for patients with small cell lung cancer. We urge you to consider this request and examine the matter of registering this medication within the territory of the Russian Federation.